Beyond RECIST: Interpreting ctDNA Dynamics as an Early Measure of Treatment Effect

• Comparing radiographic response with molecular response across different tumor contexts
• Highlighting scenarios where ctDNA change precedes or diverges from imaging outcomes
• Guiding interpretation of discordant molecular and radiographic signals

Speakers:

Zhen Su

Chief Executive Officer

Marengo Therapeutics